New FDA-Approved Treatment for RKD

The FDA has approved Gazyva® (Obinutuzumab) for Primary Membranous Nephropathy (pMN). haga clic aquí for more information. Please visit our Patient Navigation tool for support.

RECURSOS

/

ENCUENTRA UN ESPECIALISTA

/

CONTACTO

The U.S. Food and Drug Administration Approves GAZYVA (obinutuzumab) as the First and Only Treatment for Primary Membranous Nephropathy

November 2026 — The rare kidney disease (RKD) community celebrates a huge landmark milestone following the U.S. Food and Drug Administration’s (FDA) approval of GAZYVA® (obinutuzumab) as the first and only therapy for adult patients with primary membranous nephropathy (pMN) at risk of disease progression, to induce remission of proteinuria.

This historic approval provides patients with a targeted, disease-modifying treatment option for a serious condition with high unmet needs. Proteinuria serves as a key indicator of kidney damage and a critical predictor of long-term kidney preservation, making the achievement of complete remission a vital goal to maintain kidney function and prevent serious complications.

Primary membranous nephropathy (pMN) is a rare, chronic autoimmune condition that causes potentially irreversible kidney damage. When left untreated, up to 30% of patients progress to kidney failure within 10 years. People living with pMN often experience fatigue, edema (swelling), and significant physical and emotional challenges, placing a substantial human and economic burden on patients, families, and healthcare systems alike.

Gazyva is a targeted therapy designed to address B cells, a critical underlying driver of the disease. By turning decades of specialized antibody engineering into tangible outcomes, Gazyva offers a more effective approach to achieve durable disease control compared to conventional options like tacrolimus.

The FDA approval is based on robust data from the Phase III MAJESTY study, which demonstrated:

  • 36.1% of adults achieving complete remission (CR) of proteinuria at two years (104 weeks) with Gazyva versus 5.7% with tacrolimus (adjusted difference 31.1%; 95% CI: 18.2 to 44.0; p<0.001).
  • Superiority in overall remission rates (complete or partial remission) at week 104 (50% vs. 12.9%; adjusted difference 37.8%; p<0.001).
  • Complete remission at week 76 (36.1% vs. 8.6%; adjusted difference 27.4%; p<0.001).

With today’s approval, there are now 13 FDA-approved treatment options for rare, protein-spilling kidney diseases, including therapies for IgAN, focal segmental glomerulosclerosis (FSGS), C3 glomerulopathy (C3G), primary IC-MPGN, and nephrotic syndrome.

Regístrese para recibir las últimas actualizaciones de NephCure.

INSCRIBIRSE
Este campo es para fines de validación y no debe modificarse.